Business Context and Reporting Period
Company: Eli Lilly and Company
Filing Type: Form 8-K (Current Report)
Date of Report: January 14, 2025
Event: Announcement of participation in the 2025 J.P. Morgan Healthcare Conference to provide updates on earnings guidance and market trends.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of an upcoming investor presentation rather than a financial statement.
Material Changes
No material changes to historical financial results are reported in this document. The filing indicates that updates to 2024 earnings guidance and the 2025 revenue guidance range will be disclosed during the conference discussion.
Guidance, Outlook, and Management Commentary
- Guidance Update: Management will provide an update on 2024 earnings guidance and share a new revenue guidance range for 2025.
- Market Trends: The company will discuss overall market trends during the fireside chat.
- Disclosure Status: The information contained in this Item 2.02 and the attached press release (Exhibit 99.1) is furnished and not deemed "filed" under Section 18 of the Exchange Act, limiting its incorporation by reference into other filings.
Investor Verification Checklist
- Verify the specific 2024 earnings guidance update and 2025 revenue range in the attached Press Release (Exhibit 99.1) or the conference webcast.
- Review the "Webcasts & Presentations" section of the investor website for the live audio or replay of the J.P. Morgan Healthcare Conference discussion.
- Confirm that the guidance updates are not incorporated by reference into other registration statements unless expressly stated.